爱德华生命科学 EW

Bernard J. Zovighian CEO, Edwards Lifesciences Corporation Age: 57 Director Since: 2023 Edwards Board Role: Director Select Professional Experience and Highlights: Edwards Lifesciences Corporation, since 2015 Chief Executive Officer, since 2023 President, from January 2023 to May 2023 Corporate Vice President, Transcatheter Mitral and Tricuspid Therapies (TMTT), from 2018 to 2023 Vice President then Corporate Vice President, Surgical Structural Heart, from 2015 to 2018 Johnson & Johnson, a global healthcare products company Held a variety of roles with increasing levels of responsibility for nearly 20 years, including worldwide President of one of the company's divisions r. Zovighian joined Edwards Lifesciences in January 2015 as vice president and general manager of the Surgical Structural Heart business, and he later served as corporate vice president of the surgical business from 2016 until he became corporate vice president responsible for the company's Transcatheter Mitral and Tricuspid Therapies (TMTT) business in January 2018. Mr. Zovighian established a global organization focused on developing a portfolio of therapies designed to change the standard of care for mitral and tricuspid patients. Prior to joining Edwards, Mr. Zovighian held roles with increasing levels of responsibility at Johnson & Johnson for nearly 20 years, including worldwide president of one of the company's divisions. Mr. Zovighian serves as an advisory board member for the Leonard D. Schaeffer Center for Health Policy & Economics at the University of Southern California.

Mr. Chopra has been Corporate Vice President, Transcatheter Mitral and Tricuspid Therapies (TMTT) since January 2023 and expanded his responsibilities to include Surgical Structural Heart (SURG) since September 2025 and Implantable Heart Failure Management (IHFM) since October 2025. Mr. Chopra previously served as Corporate Vice President, Surgical Structural Heart, from May 2018 to January 2023. Mr. Chopra has broad experience in the medical technology industry, including global leadership in strategy, marketing, commercial operations, research and development, and program management. Prior to joining Edwards, Mr. Chopra held various roles with increasing levels of responsibility at Medtronic plc, a medical technology, services and solutions company, from 2005 to 2018, culminating in a global leadership role as Vice President and General Manager of Medtronic's Aortic Franchise. Prior to Medtronic, Mr. Chopra served as an international strategy consultant at The Parthenon Group supporting clients in various industries ranging from education to industrial manufacturing. Mr. Chopra currently serves on the boards of the CEO Leadership Alliance of Orange County and the Medical Devices Innovation Consortium (MDIC), and previously served on the boards of Edwards Lifesciences Foundation and Octane.

Mr. Bobo has been Corporate Vice President, Strategy and Corporate Development since 2007. In addition, Mr. Bobo has executive responsibility for the heart failure initiatives, as well as the U.S. healthcare solutions and commercial services team. Mr. Bobo has more than 35 years of experience in the medical technology and healthcare industry and has served in various operating roles at Edwards, including, most recently, the development of the Company's Transcatheter Mitral and Tricuspid Therapies (TMTT) strategy, Vice President and General Manager of the Surgical Structural Heart business and global valve manufacturing operations. Prior to joining Edwards in 1995, Mr. Bobo held a variety of roles with increasing levels of responsibility with American Hospital Supply Corporation and Baxter Healthcare Corporation, including research and development, business development, operations and general management. Mr. Bobo serves as a member of the board of AdvaMed, Inc. (Advanced Medical Technology Association) since May 2023. He has served on the board and executive committee of the California Life Sciences Association since 2015 and served as its chairman of the board from 2017 to 2018.The Board of Directors of Edwards Lifesciences Corporation, a Delaware corporation has received notice from Donald E. Bobo, Jr., Corporate Vice President, Strategy and Corporate Development, of his decision to retire from the Company by mid-year 2027.

Ms. Bruls has been Corporate Vice President, Europe, Middle East, Africa, Canada and Latin America (EMEACLA) since August 2024. Prior to joining the company, Ms. Bruls was the CEO of Medela Inc., a breast pump and medical vacuum company. Previously, Ms. Bruls held several senior leadership positions at Medtronic plc (Medtronic), a medical technology services and solutions company, from 2007 to 2014, including President of the Diabetes Service and Solutions division, General Manager of the Diabetes Western Europe and Canada Division and Vice President of Marketing for cardiac rhythm disease management. She also served as Vice President of Marketing at Abbott Vascular for the EMEA region. Ms. Bruls has more than 25 years of experience leading diverse teams with a mission-driven approach, coupled with a passion for innovation and technology. Ms. Bruls has been named among the Top 50 Technology CEOs (ranked ninth) by The Health Technology Report and Best CEO for 2020, 2021, and 2022 by Comparably. Since 2021, Ms. Bruls has served on the board of Coloplast, where she is a member of the Compensation and Nominating Committee.

Nicholas J. Valeriani Former CEO, Gary and Mary West Health Institute Former EVP, Johnson & Johnson Age: 68 Director Since: 2014 Edwards Board Role: Chairman of the Board Compensation and Governance Committee Member Other Public Company Directorships Previously Held: Surgalign Holdings, Inc. (formerly known as RTI Surgical Holdings, Inc.) Chair of the Compensation Committee, from 2019 to 2023 and Member, from 2016 to 2023 Member of the Nominating and Governance Committee, from 2019 to 2023 Member of the Sciences and Technology Committee, from 2016 to 2020 Sorrento Tech, Inc. (formerly Roka Bioscience, Inc.), from 2015 to 2018 Select Professional Experience and Highlights: Gary and Mary West Health Institute, an independent, nonprofit medical research organization that works to create new, more effective ways of delivering care at lower costs Chief Executive Officer, from 2012 until his retirement in 2015 Member of the Boards of the Gary and Mary West Health Institute and the Gary and Mary West Health Policy Center, since 2012 Johnson & Johnson, a global healthcare products company Company Group Chairman, Ortho Clinical Diagnostics, from 2009 to 2012 Member of the Executive Committee Vice President, Office of Strategy and Growth, from 2007 to 2009 Served 34 years in key positions, including Worldwide Chairman, Medical Devices and Diagnostics, and Corporate Vice President, Human Resources Member of the Board of AgNovos Healthcare, LLC, since 2016 Member of the Board of SPR Therapeutics, Inc., since 2018 Served on the Boards of the Robert Wood Johnson University Hospital, from 2008 to 2016, and the Center for Medical Interoperability, from 2013 to 2015.

Leslie S. Heisz Former Managing Director, Lazard Freres & Co LLC Age: 64 Director Since: 2016 Edwards Board Role: Chair of the Audit Committee Other Current Public Company Directorships: Member of the boards of the mutual funds and electronically traded funds advised by The Capital Group Companies, Inc., since 2019 Audit Committee Chair of the ETF Fund board, since 2021 Ingram Micro Holding Corporation, since 2024 Member of the Audit Committee, since 2024 Member of the Compensation Committee, since 2024 Other Public Company Directorships Previously Held: Public Storage Inc., Independent Trustee, from 2017 to 2024 Member of the Audit Committee, from 2017 to 2020 Member of the Nominating, Governance and Sustainability Committee, from 2017 to 2024 Member of the Long-Term Planning Committee, from 2020 to 2021 Ingram Micro Holding Corporation, from 2007 to 2016 Towers Watson & Co., from 2012 to 2016 HCC Insurance Holdings, Inc., from 2010 to 2014 Select Professional Experience and Highlights: Member of the Board of Kaiser Foundation Hospitals and Kaiser Foundation Health Plan, Inc., since 2015 Member of the Audit and Compliance Committee, since 2015 Member of the Finance Committee, since 2018 Member of the Governance and Community Health Committees, from 2015 to 2017 Lazard Freres & Co. LLC, a financial advisory and asset management firm, from 2003 to 2010 Senior Advisor and Managing Director Dresdner Kleinwort Wasserstein Securities Limited (and its predecessor Wasserstein Perella & Co.), the investment banking arm of Dresdner Bank AG, Mergers & Acquisitions and Corporate Finance, from 1995 to 2002 Director and Managing Director Salomon Brothers Inc., an investment banking firm, from 1987 to 1995 Associate and Vice President, Corporate Finance PricewaterhouseCoopers LLP, a registered public accounting firm, from 1982 to 1986 Staff Consultant and Senior Consultant National Association of Corporate Directors' Directorship 100 Award.

Paul A. LaViolette CEO, Pulse Biosciences, Inc., Managing Partner and Chief Operating Officer, SV Health Investors, LLC Age: 67 Director since: 2020 Edwards Board Role: Chair of the Compensation and Governance Committee Other Current Public Company Directorships: Pulse Biosciences, Inc., since 2024 Co-Chairman of the Board Other Public Company Directorships Previously Held: Misonix, Inc., from 2019 to 2021 Asensus Surgical, Inc. (formerly known as TransEnterix, Inc.), from 2014 to 2021 Thoratec Laboratories Corporation, from 2009 to 2015 Select Professional Experience and Highlights: Pulse Biosciences, Inc., a bioelectric medicine company, Chief Executive Officer, since 2025 SV Health Investors, LLC, a specialist healthcare fund management company, since 2009 Managing Partner and Chief Operating Officer, since 2014 Advanced Medical Technology Association (AdvaMed), an American medical device trade association, from 1998 to 2008 Boston Scientific Corporation, a medical device manufacturer, from 1994 to 2008 Various executive positions, including serving as Chief Operating Officer, from 2004 to 2008 C.R. Bard, Inc., a developer, manufacturer, and marketer of medical technologies, from 1984 to 1993 Various marketing and general management positions Kendall, Inc., a medical device manufacturer, from 1980 to 1984 Various marketing positions Medical Device Manufacturers Association, a national trade association providing educational and advisory assistance to medical technology companies Chairman of the Board, from 2016 to 2019 Innovation Advisory Board for the Mass General Brigham Health System Chairman of the Board, since 2015.

Kieran T. Gallahue Former Chairman and CEO, CareFusion Corporation Age: 61 Director Since: 2015 Edwards Board Role: Audit Committee Member Other Current Public Company Directorships: Envista Holdings Corporation, since 2019 Chair of the Nominating and Governance Committee, since 2019 Other Public Company Directorships Previously Held: Arena Pharmaceuticals, Inc., from 2018 to 2022 Member of the Audit Committee, from 2018 to 2022 Intersect ENT, Inc., from 2015 to 2022 Chairman of the Board, from 2020 to 2022 Member of the Audit Committee, from 2015 to 2022 CareFusion Corporation, from 2011 to 2015 Volcano Corporation, from 2007 to 2015 ResMed Inc., from 2008 to 2011 Select Professional Experience and Highlights: CareFusion Corporation, a global medical technology company (acquired by Becton, Dickinson and Company in March 2015) Chairman and Chief Executive Officer, from 2011 until his retirement in 2015 ResMed Inc., a medical technology company focused on the treatment of sleep-related breathing disorders Chief Executive Officer, from 2008 to 2011 President, from 2004 to 2011 President and Chief Operating Officer, Americas, from 2003 to 2004 Nanogen Inc., a provider of molecular diagnostic tests Various positions, including President and Chief Financial Officer, from 1998 to 2002 Prior to 1998, various marketing, sales, and financial positions within Instrumentation Laboratory, a developer of laboratory hemostasis and critical care diagnostic testing solutions, the Procter & Gamble Company, a consumer goods manufacturer, and General Electric Company, a global infrastructure and technology conglomerate Served on the Board and Executive Committee, and as Chairman of the International Committee and Treasurer of Advanced Medical Technology Association (AdvaMed), an American medical device trade association.

Ramona Sequeira President, Global Portfolio Division, Takeda Pharmaceuticals Company Limited Age: 59 Director Since: 2020 Edwards Board Role: Audit Committee Member Select Professional Experience and Highlights: Takeda Pharmaceutical Company Limited (Takeda), a biopharmaceutical company, since 2015 President, Global Portfolio Division, since 2022 Chair of the Commercialization and Launch Committee, since 2020 President of the U.S. Business Unit and Global Portfolio Commercialization, since 2020 President, from 2015 to 2020 Member of Business Review Committee and Co-Chair of Pipeline Review Committee, since 2015 Pharmaceutical Research and Manufacturers of America, a trade group, from 2015 to 2023 Chair of the Board, from 2021 to 2023, and member, from 2015 to 2023 Vice Chair, from 2021 to 2022 Treasurer, from 2019 to 2021 Eli Lilly & Company (Eli Lilly), a publicly-held company Vice President - Lilly USA, from 2013 to 2015 General Manager, UK/Northern Europe, from 2010 to 2012 Vice President, Sales - Lilly Canada, from 2005 to 2009 Associate Director, Neuroscience Marketing, from 2003 to 2005 Member of the Board of Trustees for Harvey Mudd College, from 2020 to 2023.

David T. Feinberg, MD Chairman, Oracle Health Age: 63 Director Since: 2024 Edwards Board Roles: Audit Committee Member Other Current Public Company Directorships: Humana Inc. Director and Chair of Clinic Quality Committee, since 2022 Member of the Nominating, Governance, and Sustainability Committee, since 2022 Other Public Company Directorships Previously Held: Douglas Emmett, Inc., from 2011 to 2015 and 2016 to 2024 OSI Systems, from 2010 to 2016 Select Professional Experience and Highlights: Oracle Health (formerly Cerner Corporation), a supplier of health information technology solutions, services, devices, and hardware Chairman, since 2022 President and Chief Executive Officer, from 2021 to 2022 Google, a global internet services and products company Vice President of Google Health, from 2019 to 2021 Geisinger Health Systems, a regional healthcare provider President and Chief Executive Officer, from 2015 to 2019 University of California Los Angeles (UCLA) Health, a healthcare organization President and Chief Executive Officer, from 2011 to 2019 Served for more than 20 years in a number of leadership roles including, Associate Vice Chancellor of UCLA Health Sciences, Vice Chancellor and CEO for the UCLA Hospital System, and CEO of UCLA's Ronald Reagan Medical Center Nashville Health Care Council, a healthcare industry association Chairman, since 2024.

Steven R. Loranger Former Chairman, President and CEO, ITT Corporation Age: 73 Director Since: 2016 Edwards Board Role: Compensation and Governance Committee Member Other Public Company Directorships Previously Held: Xylem Inc., since 2011 Member of the Leadership Development and Compensation Committee, from 2018 to 2024 Chair of the Finance and Technology Committee, from 2017 to 2024 Member of the Audit Committee, from 2011 to 2018 Member of the Nominating and Governance Committee, from 2011 to 2017, Chair from 2023 to 2024 FedEx Corporation, from 2006 to 2014 ITT Exelis, Inc., from 2011 to 2013 Select Professional Experience and Highlights: Xylem Inc., a global water technology provider Interim Chief Executive Officer and President, from 2013 until his retirement in 2014 ITT Corporation, a worldwide manufacturing company Chairman, President and Chief Executive Officer, from 2004 to 2011 Textron Inc., a producer of aircraft, defense and industrial products Executive Vice President and Chief Operating Officer, from 2002 to 2004 Honeywell International Inc. and its predecessor company, AlliedSignal, Inc., a diversified technology and manufacturing company Various executive positions, including serving as President and Chief Executive Officer of its Engines, Systems and Services businesses, from 1981 to 2002.

Leslie C. Davis CEO and President, UPMC Age: 66 Director Since: 2024 Edwards Board Role: Compensation and Governance Committee Member Select Professional Experience and Highlights: UPMC, a healthcare provider and insurer President and Chief Executive Officer, since 2021 Executive Vice President, Health Services Division, from 2018 to 2021 Senior Vice President and Chief Operating Officer of Health Services Division, from 2014 to 2018 UPMC Magee-Womens Hospital President, from 2004 to 2018 Thomas Jefferson University Hospital, a U.S. hospital Vice President of clinical affiliations, ambulatory programs and hospital operations Mount Sinai Medical Center, a U.S. hospital Various senior administrative positions.

On May 4, 2026, Edwards Lifesciences Corporation, a Delaware corporation announced that Theodora Mistras has been appointed as the Corporate Vice President, Chief Financial Officer of the Company, effective May 29, 2026, Ms. Mistras, has served as Chief Financial Officer of Viatris, Inc. (NASDAQ: VTRS), a global pharmaceutical and healthcare corporation, since March 1, 2024. Prior to joining Viatris, Inc. as CFO-elect in January 2024, Ms. Mistras was Managing Director, Healthcare Investment Banking at Citigroup Global Markets from September 2019 to December 2023 and prior to that was Managing Director, Healthcare Investment Banking at Goldman Sachs, where she spent over 15 years in their investment banking healthcare group.

Mr. Lippis has been Corporate Vice President, Transcatheter Aortic Valve Replacement (TAVR) since January 2026. Previously, Mr. Lippis served as the Corporate Vice President of Japan, Greater China and Asia Pacific (JAPAC) since January 2024. Mr. Lippis has more than 25 years of sales, marketing, business operations and general management experience in the pharmaceutical and medical technology industries. Mr. Lippis joined Edwards in 2010 where he led the marketing function for the Transcatheter Heart Valve business and subsequently oversaw the successful launches and therapeutic adoption of TAVR and the SAPIEN valve platforms in the U.S. and globally. From 2018 to 2023, Mr. Lippis served as Senior Vice President of Europe THV where he led sustained growth of TAVR technology in a mature market, developed a high-touch field organization and championed diversity, inclusion and belonging efforts throughout the region. In 2022, his responsibilities were expanded to include business operations and regulatory affairs for EMEACLA (Europe, Middle East, Africa, Canada and Latin America). Before joining Edwards, Mr. Lippis held sales and marketing leadership positions of increasing responsibility at Johnson & Johnson companies, Biosense Webster Inc. and Cordis Inc., based in the United States, Europe, and Asia Pacific.

Mr. Markowitz has been Corporate Vice President, Japan, Greater China, and Asia Pacific (JAPAC) since September 2025. Previously, Mr. Markowitz served as General Manager and Senior Vice President, Surgical Structural Heart since August 2023, and was responsible for R&D, operations, marketing, commercial, clinical and regulatory initiatives. Mr. Markowitz has more than 20 years of experience in the medical technology industry including leadership roles in the U.S., Europe and Japan. Prior to joining Edwards, he served as Worldwide Executive Vice President and Global Head of Endovascular Robotics at Siemens Healthineers AG, a medical technology company, from 2020 to 2023. Prior to that, Mr. Markowitz spent several years in general management and leadership roles at Johnson & Johnson, as well as functional leadership responsibilities at Boston Scientific for a decade. Mr. Markowitz's experience spans therapeutic areas including cardiovascular, neurovascular, plastic surgery, sterilization and vision. In 2024, Mr. Markowitz joined the board of Octane and previously served on the board of MassMEDIC.

Mr. Dahl has been appointed Principal Accounting Officer of the Company, effective July 1, 2024. He joined Edwards in February 2024 as Corporate Controller. Prior to joining Edwards, Mr. Dahl served in positions of increasing responsibility at Medtronic PLC, a medical device company, since May 2016, serving most recently as Vice President and Global Assistant Controller. Before joining Medtronic PLC, Mr. Dahl served as Director of Internal Audit at Polaris Industries from July 2010 to May 2016, and as a Senior Manager at Deloitte & Touche LLP from May 2002 to July 2010. Mr. Dahl holds a Bachelor of Arts in Accounting from the University of San Diego.